Flash Forward is a show about possible (and not so possible) future scenarios. What would the warranty on a sex robot look like? How would diplomacy work if we couldn’t lie? Could there ever be a fecal transplant black market? (Complicated, it wouldn’t, and yes, respectively, in case you’re curious.) Hosted and produced by award winning science journalist Rose Eveleth, each episode combines audio drama and journalism to go deep on potential tomorrows, and uncovers what those futures might re ...
…
continue reading
Player FM - Internet Radio Done Right
94 subscribers
Checked 4h ago
Added eight years ago
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Similar to Research To Practice | Oncology Videos
Emergency Medicine Cases – Where the Experts Keep You in the Know. For show notes, quizzes, videos and more learning tools please visit emergencymedicinecases.com
…
continue reading
The BMJ brings you interviews with the people who are shaping medicine and science around the world.
…
continue reading
Come dive into one of the curiously delightful conversations overheard at National Geographic’s headquarters, as we follow explorers, photographers, and scientists to the edges of our big, weird, beautiful world. Hosted by Peter Gwin and Amy Briggs.
…
continue reading
Help me fill in the blanks of the practice of ED Critical Care. In this podcast, we discuss all things related to the crashing, critically ill patient in the Emergency Department. Find the show notes at emcrit.org.
…
continue reading
Concise summaries of everything published in the latest weekly issue of the New England Journal of Medicine (NEJM). NEJM publishes new medical research findings, review articles, and editorial opinion on topics of importance to biomedical science and clinical practice.
…
continue reading
Science Friction has a new series: Cooked. We dig into food science pickles. Why are studies showing that ice cream could be good for you? Do we really need as many electrolytes as the internet says? And why are people feeling good on the carnivore diet? Nutrition and food scientist Dr Emma Beckett takes us through what the evidence says about food categories and ingredients like meat, dairy and salt — and unpick why nutrition studies can be so conflicting and confusing. Airs Wednesday 11:30 ...
…
continue reading
We humans could have a bright future ahead of us that lasts billions of years. But we have to survive the next 200 years first. Join Josh Clark of Stuff You Should Know for a 10-episode deep dive that explores the future of humanity and finds dangers we have never encountered before lurking just ahead. And if we humans are alone in the universe, if we don't survive intelligent life dies out with us too.
…
continue reading
How many organs could you donate and remain alive? How many planet Earths could fit inside the Sun? How high is a giraffe's blood pressure? Why is the sea blue? To find out, Ask The Naked Scientists!
…
continue reading
How can we, humans, look at our relationship to nature differently? In season three of Going Wild, on top of stories about animals, we invite you to journey through the entire ecological web — from the tiniest of life forms to apex predators — alongside the scientists, activists and adventurers who study it. Wildlife biologist and host Dr. Rae Wynn-Grant has been studying wild animals in their natural habitats all over the world for years. Our award-winning podcast takes you inside the hidde ...
…
continue reading
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
))
Podcasts Worth a Listen
SPONSORED
<
<div class="span index">1</div> <span><a class="" data-remote="true" data-type="html" href="/series/all-about-change">All About Change</a></span>
How do we build an inclusive world? Hear intimate and in-depth conversations with changemakers on disability rights, youth mental health advocacy, prison reform, grassroots activism, and more. First-hand stories about activism, change, and courage from people who are changing the world: from how a teen mom became the Planned Parenthood CEO, to NBA player Kevin Love on mental health in professional sports, to Beetlejuice actress Geena Davis on Hollywood’s role in women’s rights. All About Change is hosted by Jay Ruderman, whose life’s work is seeking social justice and inclusion for people with disabilities worldwide. Join Jay as he interviews iconic guests who have gone through adversity and harnessed their experiences to better the world. This show ultimately offers the message of hope that we need to keep going. All About Change is a production of the Ruderman Family Foundation. Listen and subscribe to All About Change wherever you get podcasts. https://allaboutchangepodcast.com/
Research To Practice | Oncology Videos
Mark all (un)played …
Manage series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.
…
continue reading
1526 episodes
Share
Mark all (un)played …
Manage series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.
…
continue reading
1526 episodes
All episodes
×
R
Research To Practice | Oncology Videos
1 Neurofibromatosis Type 1 Plexiform Neurofibromas — An interview with Dr Christopher L Moertel 49:28
49:28 
Play Later 
Play Later 
Lists 
Like 
Liked49:28
Play Later
Play Later
Lists
Like
LikedFeaturing an interview with Dr Christopher L Moertel, including the following topics: Overview of neurofibromatosis type 1(NF1) (0:00) Cancer in NF1 (8:38) Dermatologic manifestations of NF1 (16:57) Treatment options for NF1 (20:43) Malignant peripheral nerve sheath tumors (MPNST) (25:14) FDA-approved MEK inhibitors for NF1 plexiform neurofibromas (28:36) Specializing in NF (44:44) CME information and select publications…
R
Research To Practice | Oncology Videos
1 Neurofibromatosis Type 1 Plexiform Neurofibromas — An interview with Dr Christopher L Moertel (Companion Faculty Lecture) 54:16
54:16 Play Later Play Later Lists Like Liked54:16
Play Later Play Later Lists Like LikedFeaturing a slide presentation and related discussion from Dr Christopher L Moertel, including the following topics: Overview of neurofibromatosis (0:00) Common clinical manifestations of neurofibromatosis type 1 (NF1) (14:13) Role of MEK inhibitors in the management of NF1 plexiform neurofibromas (29:30) CME information and select publications…
R
Research To Practice | Oncology Videos
1 HR-Positive Breast Cancer — An Interview with Dr Sara A Hurvitz on the Role of Endocrine-Based Therapy 1:03:10
1:03:10 Play Later Play Later Lists Like Liked1:03:10
Play Later Play Later Lists Like LikedFeaturing an interview with Dr Sara A Hurvitz, including the following topics: Role of endocrine therapy in the management of HER2-positive breast cancer; implications of the Phase III PATINA study (0:00) Case: A woman in her mid 60s with node-negative, HR-positive, HER2-negative localized breast cancer and a Recurrence Score® of 28 (8:38) Available data guiding the selection of an adjuvant CDK4/6 inhibitor (12:49) Selection of a CDK4/6 inhibitor in the metastatic setting (23:16) Available therapies for patients with HR-positive metastatic breast cancer (mBC) and PIK3CA mutations; implications of the Phase III INAVO120 study (29:17) Case: A woman in her early 60s with HR-positive, HER2-negative mBC with short duration of benefit from a first-line CDK4/6 inhibitor and an aromatase inhibitor (AI) and coexisting PIK3CA and ESR1 mutations (37:11) Available data with approved and investigational oral SERDs (selective estrogen receptor degraders) (43:23) Case: A woman in her early 70s with HR-positive, HER2-negative mBC and an ESR1 mutation detected on disease progression after durable responses to first-line endocrine therapy and second-line CDK4/6 inhibitor with an AI (51:38) Selection of therapy for patients with HR-positive mBC and coexisting targetable genetic mutations (53:11) Case: A woman in her late 50s with HR-positive, HER2-negative mBC and an ESR1 mutation detected on disease progression after first-line CDK4/6 inhibitor with an AI (1:00:17) CME information and select publications…
R
Research To Practice | Oncology Videos
1 Bispecific Antibodies in Multiple Myeloma — An Interview with Dr Tiffany A Richards for Oncology Nurses 1:05:16
1:05:16 Play Later Play Later Lists Like Liked1:05:16
Play Later Play Later Lists Like LikedFeaturing an interview with Dr Tiffany A Richards, including the following topics: Current treatment landscape for multiple myeloma (MM) (0:00) CAR (chimeric antigen receptor) T-cell therapy for the management of MM (10:22) Bispecific antibodies for relapsed/refractory MM (24:26) Case: A woman in her early 80s with relapsed MM receives teclistamab (35:56) Case: A man in his early 70s with multiregimen-refractory MM receives linvoseltamab on a clinical trial (44:06) Case: A woman in her early 60s with relapsed MM and extramedullary disease receives talquetamab (48:38) Role of nurses in transitions of care for patients with MM (53:15) Case: A man in his mid 70s with heavily pretreated MM experiences a response to teclistamab (58:56) Risk of second cancers with bispecific antibodies and other immunotherapy-based treatment approaches (1:00:55) NCPD information and select publications…
R
Research To Practice | Oncology Videos
1 ER-Positive Metastatic Breast Cancer | 5-Minute Journal Club Issue 6 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer 16:10
16:10 Play Later Play Later Lists Like Liked16:10
Play Later Play Later Lists Like LikedFeaturing an interview with Dr Komal Jhaveri, including the following topics: Emerging treatment options for advanced ER-positive breast cancer (0:00) Burstein H. Emerging treatment options for advanced ER+ breast cancer. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01 Discussant. Elacestrant real-world progression-free survival for adult patients with ER-positive, HER2-negative advanced breast cancer: A retrospective analysis using insurance claims in the United States (7:28) Swallow E et al. Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: A retrospective analysis using insurance claims in the United States. San Antonio Breast Cancer Symposium 2024;Abstract P3-10-08. Ongoing clinical trials involving oral SERDs (9:03) Kaklamani V et al. ELCIN: Elacestrant in women and men with CDK4/6 inhibitor (CDK4/6i)-naïve estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (mBC): An open-label multicenter phase 2 study. San Antonio Breast Cancer Symposium 2024;Abstract P2-08-20. An adjuvant endocrine-based therapy study of camizestrant (AZD9833) in ER+/HER2- early breast cancer (CAMBRIA-2). NCT05952557 Bardia A et al. ELEGANT: Elacestrant versus standard endocrine therapy in women & men with node-positive, estrogen receptor-positive, HER2-negative, early breast cancer with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study. San Antonio Breast Cancer Symposium 2024;Abstract P2-08-21. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer (13:48) Lloyd MR et al. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. Nat Rev Clin Oncol 2024;21(10):743-61. Abstract CME information and select publications…
R
Research To Practice | Oncology Videos
1 Bispecific Antibodies in Lymphoma Part 1 — An Interview with Ms Robin Klebig for Oncology Nurses 1:05:59
1:05:59 Play Later Play Later Lists Like Liked1:05:59
Play Later Play Later Lists Like LikedFeaturing an interview with Ms Robin Klebig, including the following topics: Overview of the natural history and treatment landscapes of lymphoma subtypes (0:00) Structure and mechanisms of action of bispecific antibodies (23:41) Similarities and differences among the various approved and investigational CD20 x CD3 bispecific antibodies for non-Hodgkin lymphoma (28:14) Case: A man in his early 50s with multiagent/multiregimen-refractory follicular lymphoma who experienced disease progression with chimeric antigen receptor T-cell therapy now receives mosunetuzumab (39:14) Case: A woman in her mid 60s with relapsed/refractory (R/R) diffuse large B-cell lymphoma receives glofitamab (49:08) Case: A man in his mid 60s with R/R high-grade B-cell lymphoma with MYC and Bcl-2 rearrangements receives epcoritamab (52:57) Case: A man in his early 60s with composite lymphoma receives epcoritamab (56:55) NCPD information and select publications…
R
Research To Practice | Oncology Videos
1 Renal Cell Carcinoma — Proceedings from a Session Held in Conjunction with the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) 1:58:35
1:58:35 Play Later Play Later Lists Like Liked1:58:35
Play Later Play Later Lists Like LikedFeaturing perspectives from Dr Thomas E Hutson, Dr Rana R McKay, Dr Sumanta Kumar Pal and Dr Tian Zhang, moderated by Dr Pal, including the following topics: Introduction (0:00) Immunotherapeutic Strategies for Localized and Metastatic Clear Cell Renal Cell Carcinoma (RCC) — Dr Hutson (2:34) Optimal Management of Relapsed/Refractory RCC — Dr Zhang (32:49) Role of HIF-2α Inhibitors in the Treatment of Sporadic and von Hippel-Lindau-Associated RCC — Dr McKay (1:04:02) Current and Future Care of Patients with Non-Clear Cell RCC — Dr Pal (1:33:13) CME information and select publications…
R
Research To Practice | Oncology Videos
1 Colorectal Cancer — Year in Review Series on Relevant New Datasets and Advances 58:40
58:40 Play Later Play Later Lists Like Liked58:40
Play Later Play Later Lists Like LikedFeaturing perspectives from Dr Scott Kopetz and Dr Jeffrey Meyerhardt, including the following topics: Introduction (0:00) Cell-Free DNA Molecular Residual Disease Assays in Clinical Practice (3:25) Immunotherapy for Localized and Metastatic Microsatellite Instability-High Colorectal Cancer (28:27) Other Important Datasets (46:06) CME information and select publications…
R
Research To Practice | Oncology Videos
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Colorectal Cancer | Faculty Presentation 2: Advances in the Management of Metastatic CRC (mCRC) — Scott Kopetz, MD, PhD CME information and select publications
R
Research To Practice | Oncology Videos
1 Colorectal Cancer | Jeffrey Meyerhardt, MD, MPH 36:43
36:43 Play Later Play Later Lists Like Liked36:43
Play Later Play Later Lists Like LikedYear in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Colorectal Cancer | Faculty Presentation 1: Optimizing the Care of Patients with Localized Colorectal Cancer (CRC) — Jeffrey Meyerhardt, MD, MPH CME information and select publications
R
Research To Practice | Oncology Videos
1 Localized Breast Cancer — Examining the Current Use of Genetic Testing and Related Clinical Management 59:49
59:49 Play Later Play Later Lists Like Liked59:49
Play Later Play Later Lists Like LikedFeaturing perspectives from Dr Kevin S Hughes and Dr Mark Robson, including the following topics: Introduction (0:00) Optimal Approach to Genetic Testing for Patients with Localized Breast Cancer (BC) — Dr Hughes (10:22) Available Data with and Practical Application of PARP Inhibition as Adjuvant Therapy for Patients with BC — Dr Robson (38:06) CME information and select publications…
R
Research To Practice | Oncology Videos
1 Urothelial Bladder Cancer and Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) 1:57:43
1:57:43 Play Later Play Later Lists Like Liked1:57:43
Play Later Play Later Lists Like LikedFeaturing perspectives from Dr Terence Friedlander and Dr Matthew D Galsky, Dr Neeraj Agarwal and Dr Andrew J Armstrong, moderated by Dr Elisabeth I Heath, including the following topics: Introduction (0:00) Role of Antibody-Drug Conjugates (ADCs) in Front-Line Therapy for Metastatic Urothelial Bladder Cancer (mUBC) — Dr Friedlander (2:53) Evidence-Based Use of ADCs for Relapsed/Refractory mUBC — Dr Galsky (33:04) Evolving Role of Treatment Intensification with Androgen Receptor Pathway Inhibitors for Nonmetastatic and Metastatic Prostate Cancer — Dr Armstrong (1:01:28) Optimal Integration of PARP Inhibitors into Therapy for Prostate Cancer — Dr Agarwal (1:27:49) CME information and select publications…
R
Research To Practice | Oncology Videos
1 5-Minute Journal Club Issue 5 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer 18:31
18:31 Play Later Play Later Lists Like Liked18:31
Play Later Play Later Lists Like LikedFeaturing an interview with Dr Komal Jhaveri, including the following topics: Imlunestrant, an oral selective estrogen receptor degrader (SERD), with and without abemaciclib for ER-positive, HER2-negative advanced or metastatic breast cancer (0:00) Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): Results of the phase 3 EMBER-3 trial. San Antonio Breast Cancer Symposium 2024; Abstract GS1-01 . Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2024;[Online ahead of print]. Abstract Rugo HS et al. Elacestrant abemaciclib (abema) combination in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced or metastatic breast cancer (mBC). San Antonio Breast Cancer Symposium 2024; Abstract PS7-07. Elacestrant for ER-positive, HER2-negative metastatic breast cancer with ESR1-mutated tumors: Subgroup analyses from the Phase III EMERALD trial by duration of prior endocrine therapy with a CDK4/6 inhibitor and in clinical subgroups (7:40) Bardia A et al. Elacestrant in ER+, HER2- MBC with ESR1-mutated tumors: Subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Clin Cancer Res 2024;30(19):4299-309. Abstract Pharmacokinetics and safety of imlunestrant in patients with hepatic impairment (11:25) Wang XA et al. Evaluation of pharmacokinetics and safety of imlunestrant in participants with hepatic impairment. San Antonio Breast Cancer Symposium 2024;Abstract P4-10-07. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer (13:15) Lloyd MR et al. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. Nat Rev Clin Oncol 2024;21(10):743-61. Abstract CME information and select publications…
R
Research To Practice | Oncology Videos
1 Biliary Tract Cancers — Reviewing Patient Cases with Prof John Bridgewater 58:01
58:01 Play Later Play Later Lists Like Liked58:01
Play Later Play Later Lists Like LikedFeaturing perspectives from Prof John Bridgewater, including the following topics: Introduction: Biology and Epidemiology; Classification (0:00) Localized Biliary Tract Cancers (6:25) First-Line Treatment of Metastatic BTC (20:04) HER2-Positive Advanced BTC (24:22) Management of Mixed Hepatocellular Carcinoma/BTC Tumors (43:18) Advanced Cholangiocarcinoma with an FGFR2 Fusion (47:59) Other Important Issues in BTC (52:33) CME information and select publications…
R
Research To Practice | Oncology Videos
1 Relapsed/Refractory Diffuse Large B-Cell Lymphoma — A Roundtable Discussion on Current and Future Management Strategies 2:32:47
2:32:47 Play Later Play Later Lists Like Liked2:32:47
Play Later Play Later Lists Like LikedFeaturing slide presentations and related discussion from Prof Martin Hutchings, Dr Manali Kamdar, Dr Matthew Lunning and Prof Gilles Salles, including the following topics: Evolving Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (0:00) Case: A 61-year-old man with Stage IV non-GCB DLBCL receives R-CHOP but experiences disease progression 8 months later (30:39) Case: A 68-year-old man with double-hit DLBCL who experiences disease progression on chemotherapy and second-line CAR T-cell therapy receives glofitamab (39:22) Incorporation of Bispecific Antibody Therapy into DLBCL Management — Prof Hutchings (45:25) Case: A 42-year-old man with progressive DLBCL refractory to 2 lines of therapy receives glofitamab with a durable response (1:07:30) Case: An 81-year-old woman with multiregimen-refractory DLBCL experiences a prolonged response to epcoritamab (1:14:25) Case: A 69-year-old man with follicular lymphoma transformed to DLBCL and refractory to 3 lines of treatment receives glofitamab (1:21:48) Selection and Sequencing of Other Available Therapies for Relapsed/Refractory (R/R) DLBCL — Prof Salles (1:24:37) Case: An 82-year-old woman with follicular lymphoma transformed to DLBCL receives tafasitamab/lenalidomide (1:42:05) Case: A 69-year-old man with urinary bladder carcinoma and recurrent GCB DLBCL receives loncastuximab tesirine (1:46:26) Promising Investigational Approaches for Patients with R/R DLBCL — Dr Lunning (2:00:37) Case: An 80-year-old woman with multiregimen-refractory GCB DLBCL seeks treatment requiring minimal clinic visits and receives loncastuximab tesirine (2:15:59) Case: A 54-year-old man with primary refractory non-GCB DLBCL receives CAR T-cell therapy, and follow-up imaging on day 29 demonstrates a Deauville score of 4 (2:25:22) CME information and select publications…
Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.
Similar to Research To Practice | Oncology Videos
Flash Forward is a show about possible (and not so possible) future scenarios. What would the warranty on a sex robot look like? How would diplomacy work if we couldn’t lie? Could there ever be a fecal transplant black market? (Complicated, it wouldn’t, and yes, respectively, in case you’re curious.) Hosted and produced by award winning science journalist Rose Eveleth, each episode combines audio drama and journalism to go deep on potential tomorrows, and uncovers what those futures might re ...
…
continue reading
Emergency Medicine Cases – Where the Experts Keep You in the Know. For show notes, quizzes, videos and more learning tools please visit emergencymedicinecases.com
…
continue reading
The BMJ brings you interviews with the people who are shaping medicine and science around the world.
…
continue reading
Come dive into one of the curiously delightful conversations overheard at National Geographic’s headquarters, as we follow explorers, photographers, and scientists to the edges of our big, weird, beautiful world. Hosted by Peter Gwin and Amy Briggs.
…
continue reading
Help me fill in the blanks of the practice of ED Critical Care. In this podcast, we discuss all things related to the crashing, critically ill patient in the Emergency Department. Find the show notes at emcrit.org.
…
continue reading
Concise summaries of everything published in the latest weekly issue of the New England Journal of Medicine (NEJM). NEJM publishes new medical research findings, review articles, and editorial opinion on topics of importance to biomedical science and clinical practice.
…
continue reading
Science Friction has a new series: Cooked. We dig into food science pickles. Why are studies showing that ice cream could be good for you? Do we really need as many electrolytes as the internet says? And why are people feeling good on the carnivore diet? Nutrition and food scientist Dr Emma Beckett takes us through what the evidence says about food categories and ingredients like meat, dairy and salt — and unpick why nutrition studies can be so conflicting and confusing. Airs Wednesday 11:30 ...
…
continue reading
We humans could have a bright future ahead of us that lasts billions of years. But we have to survive the next 200 years first. Join Josh Clark of Stuff You Should Know for a 10-episode deep dive that explores the future of humanity and finds dangers we have never encountered before lurking just ahead. And if we humans are alone in the universe, if we don't survive intelligent life dies out with us too.
…
continue reading
How many organs could you donate and remain alive? How many planet Earths could fit inside the Sun? How high is a giraffe's blood pressure? Why is the sea blue? To find out, Ask The Naked Scientists!
…
continue reading
How can we, humans, look at our relationship to nature differently? In season three of Going Wild, on top of stories about animals, we invite you to journey through the entire ecological web — from the tiniest of life forms to apex predators — alongside the scientists, activists and adventurers who study it. Wildlife biologist and host Dr. Rae Wynn-Grant has been studying wild animals in their natural habitats all over the world for years. Our award-winning podcast takes you inside the hidde ...
…
continue reading
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
